Which has stronger valuation & earnings, LW or MED?

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lamb Weston $6.61B 0.99 $290M $2.08 22.93 Medifast $385.79M 0.35 -$18.67M -$2.33 N/A

Is LW or MED more profitable?

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Lamb Weston 4.39% 23.33% 5.72% Medifast -8.08% -6.69% -5.25%

Does the media favor LW or MED?

In the previous week, Lamb Weston had 2 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Lamb Weston and 1 mentions for Medifast. Lamb Weston's average media sentiment score of 1.31 beat Medifast's score of 1.04 indicating that Lamb Weston is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lamb Weston 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MED or NOMD?

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.35 -$18.67M -$2.33 N/A Nomad Foods $3.43B 0.45 $154.66M $1.02 10.75

Is MED or NOMD more profitable?

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -8.08% -6.69% -5.25% Nomad Foods 4.20% 8.88% 3.53%

Does the media prefer MED or NOMD?

In the previous week, Medifast and Medifast both had 1 articles in the media. Medifast's average media sentiment score of 1.04 beat Nomad Foods' score of 0.00 indicating that Medifast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nomad Foods 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, PRE or MED?

Medifast has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prenetics Global $154.59M 2.56 -$37.71M -$4.16 N/A Medifast $385.79M 0.35 -$18.67M -$2.33 N/A

Do analysts prefer MED or USNA?

Medifast presently has a consensus price target of $12.00, suggesting a potential downside of 0.32%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than USANA Health Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medifast 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 USANA Health Sciences 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to NAGE or MED?

In the previous week, Niagen Bioscience had 2 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Niagen Bioscience and 1 mentions for Medifast. Medifast's average media sentiment score of 1.04 beat Niagen Bioscience's score of 0.81 indicating that Medifast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medifast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medifast (MED) Competitors

$12.04 -0.01 (-0.10%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$12.04 +0.01 (+0.06%)

As of 09/11/2026 07:30 PM Eastern

Compare

MED vs. LW, NOMD, PRE, USNA, and NAGE

Should you buy Medifast stock or one of its competitors? Medifast's main competitors and comparable companies include Lamb Weston (LW), Nomad Foods (NOMD), Prenetics Global (PRE), USANA Health Sciences (USNA), and Niagen Bioscience (NAGE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "consumer staples" sector.

How does Medifast compare to Lamb Weston?

Lamb Weston (NYSE:LW) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Lamb Weston has a net margin of 4.39% compared to Medifast's net margin of -8.08%. Lamb Weston's return on equity of 23.33% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lamb Weston	4.39%	23.33%	5.72%
Medifast	-8.08%	-6.69%	-5.25%

Lamb Weston has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Medifast has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Lamb Weston currently has a consensus target price of $53.36, suggesting a potential upside of 11.87%. Medifast has a consensus target price of $12.00, suggesting a potential downside of 0.32%. Given Lamb Weston's stronger consensus rating and higher possible upside, equities analysts clearly believe Lamb Weston is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lamb Weston	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

89.6% of Lamb Weston shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 1.0% of Lamb Weston shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lamb Weston	$6.61B	0.99	$290M	$2.08	22.93
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A

In the previous week, Lamb Weston had 2 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Lamb Weston and 1 mentions for Medifast. Lamb Weston's average media sentiment score of 1.31 beat Medifast's score of 1.04 indicating that Lamb Weston is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lamb Weston	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lamb Weston beats Medifast on 13 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Medifast (NYSE:MED) and Nomad Foods (NYSE:NOMD) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Medifast has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Nomad Foods has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Medifast currently has a consensus target price of $12.00, suggesting a potential downside of 0.32%. Nomad Foods has a consensus target price of $13.25, suggesting a potential upside of 20.79%. Given Nomad Foods' stronger consensus rating and higher possible upside, analysts clearly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Nomad Foods has a net margin of 4.20% compared to Medifast's net margin of -8.08%. Nomad Foods' return on equity of 8.88% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
Nomad Foods	4.20%	8.88%	3.53%

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A
Nomad Foods	$3.43B	0.45	$154.66M	$1.02	10.75

In the previous week, Medifast and Medifast both had 1 articles in the media. Medifast's average media sentiment score of 1.04 beat Nomad Foods' score of 0.00 indicating that Medifast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nomad Foods	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.5% of Medifast shares are held by institutional investors. Comparatively, 75.3% of Nomad Foods shares are held by institutional investors. 3.7% of Medifast shares are held by company insiders. Comparatively, 17.3% of Nomad Foods shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Nomad Foods beats Medifast on 12 of the 15 factors compared between the two stocks.

How does Medifast compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Prenetics Global has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Medifast has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

In the previous week, Prenetics Global and Prenetics Global both had 1 articles in the media. Prenetics Global's average media sentiment score of 1.89 beat Medifast's score of 1.04 indicating that Prenetics Global is being referred to more favorably in the media.

Company	Overall Sentiment
Prenetics Global	Very Positive
Medifast	Positive

Prenetics Global presently has a consensus price target of $34.80, indicating a potential upside of 48.27%. Medifast has a consensus price target of $12.00, indicating a potential downside of 0.32%. Given Prenetics Global's stronger consensus rating and higher possible upside, equities research analysts clearly believe Prenetics Global is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medifast has a net margin of -8.08% compared to Prenetics Global's net margin of -47.43%. Medifast's return on equity of -6.69% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-47.43%	-21.41%	-15.56%
Medifast	-8.08%	-6.69%	-5.25%

Medifast has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$154.59M	2.56	-$37.71M	-$4.16	N/A
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A

Summary

Medifast beats Prenetics Global on 9 of the 15 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

Medifast (NYSE:MED) and USANA Health Sciences (NYSE:USNA) are both small-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

USANA Health Sciences has a net margin of -2.43% compared to Medifast's net margin of -8.08%. USANA Health Sciences' return on equity of 3.41% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-8.08%	-6.69%	-5.25%
USANA Health Sciences	-2.43%	3.41%	2.50%

Medifast has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

In the previous week, Medifast had 1 more articles in the media than USANA Health Sciences. MarketBeat recorded 1 mentions for Medifast and 0 mentions for USANA Health Sciences. Medifast's average media sentiment score of 1.04 beat USANA Health Sciences' score of 0.81 indicating that Medifast is being referred to more favorably in the media.

Company	Overall Sentiment
Medifast	Positive
USANA Health Sciences	Positive

95.5% of Medifast shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 3.7% of Medifast shares are owned by company insiders. Comparatively, 0.8% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

USANA Health Sciences has higher revenue and earnings than Medifast. USANA Health Sciences is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A
USANA Health Sciences	$913.36M	0.30	$10.76M	-$1.21	N/A

Medifast presently has a consensus price target of $12.00, suggesting a potential downside of 0.32%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
USANA Health Sciences	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Medifast beats USANA Health Sciences on 9 of the 15 factors compared between the two stocks.

How does Medifast compare to Niagen Bioscience?

Niagen Bioscience (NASDAQ:NAGE) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 3.7% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Niagen Bioscience has a net margin of 12.39% compared to Medifast's net margin of -8.08%. Niagen Bioscience's return on equity of 17.95% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Medifast	-8.08%	-6.69%	-5.25%

In the previous week, Niagen Bioscience had 2 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Niagen Bioscience and 1 mentions for Medifast. Medifast's average media sentiment score of 1.04 beat Niagen Bioscience's score of 0.81 indicating that Medifast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medifast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience has higher earnings, but lower revenue than Medifast. Medifast is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.87	$17.38M	$0.18	16.89
Medifast	$385.79M	0.35	-$18.67M	-$2.33	N/A

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 239.91%. Medifast has a consensus target price of $12.00, indicating a potential downside of 0.32%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Medifast has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

Summary

Niagen Bioscience beats Medifast on 14 of the 17 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	Personal Care Products Industry	Consumer Staples Sector	NYSE Exchange
Market Cap	$134.73M	$22.66B	$15.57B	$23.19B
Dividend Yield	N/A	4.50%	3.26%	3.56%
P/E Ratio	-5.17	20.30	14.06	28.69
Price / Sales	0.35	12.53	262,948.36	99.79
Price / Cash	29.03	26.78	56.81	33.82
Price / Book	0.67	2.88	4.76	4.74
Net Income	-$18.67M	$1.13B	$837.55M	$1.07B
7 Day Performance	-4.65%	-1.85%	-1.42%	-1.99%
1 Month Performance	3.96%	-0.60%	-1.60%	-2.68%
1 Year Performance	-13.89%	-15.14%	10.48%	10.45%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	1.2036 of 5 stars	$12.04 -0.1%	$12.00 -0.3%	-13.5%	$134.73M	$385.79M	N/A	870
LW Lamb Weston	3.2624 of 5 stars	$49.88 -1.1%	$53.36 +7.0%	-16.6%	$6.86B	$6.61B	23.98	10,000	Positive News
NOMD Nomad Foods	4.9519 of 5 stars	$11.65 +1.3%	$13.25 +13.7%	-23.0%	$1.63B	$3.43B	11.42	7,752
PRE Prenetics Global	4.0221 of 5 stars	$25.44 -0.7%	$34.80 +36.8%	+164.9%	$429.28M	$154.59M	N/A	1	Positive News
USNA USANA Health Sciences	2.2473 of 5 stars	$14.88 +3.1%	N/A	-51.3%	$276.42M	$925.26M	N/A	1,570

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, USNA, and NAGE

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to Prenetics Global?

Summary

How does Medifast compare to USANA Health Sciences?

Summary

How does Medifast compare to Niagen Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, PRE, USNA, and NAGE

How does Medifast compare to Lamb Weston?

Is LW or MED more profitable?

Which has more volatility and risk, LW or MED?

Do analysts prefer LW or MED?

Do insiders and institutionals hold more shares of LW or MED?

Which has stronger valuation & earnings, LW or MED?

Does the media favor LW or MED?

Summary

How does Medifast compare to Nomad Foods?

Which has more volatility & risk, MED or NOMD?

Do analysts prefer MED or NOMD?

Is MED or NOMD more profitable?

Which has stronger valuation & earnings, MED or NOMD?

Does the media prefer MED or NOMD?

Do insiders & institutionals hold more shares of MED or NOMD?

Summary

How does Medifast compare to Prenetics Global?

Which has more risk & volatility, PRE or MED?

Does the media favor PRE or MED?

Do analysts rate PRE or MED?

Do insiders and institutionals have more ownership in PRE or MED?

Is PRE or MED more profitable?

Which has higher valuation and earnings, PRE or MED?

Summary

How does Medifast compare to USANA Health Sciences?

Is MED or USNA more profitable?

Which has more risk & volatility, MED or USNA?

Does the media refer more to MED or USNA?

Do insiders & institutionals hold more shares of MED or USNA?

Which has better valuation & earnings, MED or USNA?

Do analysts prefer MED or USNA?

Summary

How does Medifast compare to Niagen Bioscience?

Do institutionals & insiders have more ownership in NAGE or MED?

Is NAGE or MED more profitable?

Does the media refer more to NAGE or MED?

Which has higher valuation and earnings, NAGE or MED?

Do analysts recommend NAGE or MED?

Which has more volatility & risk, NAGE or MED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools